IDP Pharma has closed today a 2M€ private funding round. The company will allocate the funding to start clinical activities of IDP-121 (solid and haem tumors), to complete the formulation of IDP-233 (neuroendocrine tumors) and to exploit its technological platform (IDP Platform).

The company has received further support from RETOS public program (1M€) to advance innovative research in collaboration with CIMA and Univertisy of Navarra.

IDP Pharma has closed a 2,5M€ investment round. The company will allocate the capital to complete the preclinical development of its first product, push forward its new neuroendocrine tumor program and to exploit its technological platform (IDP platform).

IDP Pharma has closed a 1,5M€ seed investment round. The private funding adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ) in collaboration with Leitat, University of Salamanca (FICUS) and BCN Peptides. The company will allocate the capital to advance the preclinical development of its first product for cancer treatment and to continue developing its technology: IDP-Platform.